 | • レポートコード：TPM-C03110 • 出版社/出版日：Transparency Market Research / 2019年2月15日 • レポート形態：英文、PDF、195ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、黄斑変性症治療の世界市場について調べ、黄斑変性症治療の世界規模、市場動向、市場環境、適応症別（ドライタイプ加齢黄斑変性症（dAMD）、ウェットタイプ加齢黄斑変性症（wAMD））分析、薬剤クラス別（抗血管内皮増殖因子、その他）分析、流通経路別（病院、眼科診療所、通院外科診療所）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。 ・序文・調査範囲・調査手法 ・エグゼクティブサマリー ・黄斑変性症治療の世界市場動向 ・黄斑変性症治療の世界市場環境 ・黄斑変性症治療の世界市場規模 ・黄斑変性症治療の世界市場規模：適応症別（ドライタイプ加齢黄斑変性症（dAMD）、ウェットタイプ加齢黄斑変性症（wAMD）） ・黄斑変性症治療の世界市場規模：薬剤クラス別（抗血管内皮増殖因子、その他） ・黄斑変性症治療の世界市場規模：流通経路別（病院、眼科診療所、通院外科診療所） ・黄斑変性症治療の世界市場：地域別市場規模・分析 ・黄斑変性症治療の北米市場規模・予測 ・黄斑変性症治療のアメリカ市場規模・予測 ・黄斑変性症治療の中南米市場規模・予測 ・黄斑変性症治療のヨーロッパ市場規模・予測 ・黄斑変性症治療のアジア市場規模・予測 ・黄斑変性症治療の日本市場規模・予測 ・黄斑変性症治療の中国市場規模・予測 ・黄斑変性症治療のインド市場規模・予測 ・黄斑変性症治療の中東市場規模・予測 ・黄斑変性症治療のアフリカ市場規模・予測 ・競争状況・関連企業情報 |
Macular Degeneration Treatment Market: Overview
This report on the global macular degeneration treatment market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on disease indication, drug class, distribution channel, and region. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. Additionally, the section comprises a competitive matrix and company profiles with business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global macular degeneration treatment market.
Global Macular Degeneration Treatment Market: Key Segments
Based on disease indication, the global macular degeneration treatment market has been segmented into dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), and others. In terms of drug class, the market has been classified into anti-vascular endothelial growth factor and others. Based on distribution channel, the market has been categorized into hospitals, ophthalmic clinics, and ambulatory surgical centers. The global macular degeneration treatment market has been analyzed based on increasing regulatory scrutiny, technology trends, expenditure on emerging technologies, pipeline molecules and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Macular Degeneration Treatment Market: Regional Outlook
In terms of region, the global macular degeneration treatment market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period of 2016 to 2026, along with their respective CAGRs for the forecast period 2018-2026, considering 2017 as the base year.
Companies Mentioned in the Report
The report profiles major players operating in the global macular degeneration treatment market in terms of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report include Allergan, Inc., Pfizer, Inc., Novartis AG., REGENERON PHARMACEUTICALS, INC., Santen Pharmaceuticals, Valeant Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sanofi, and Bayer AG.
The global macular degeneration treatment market has been segmented as follows:
Global Macular Degeneration Treatment Market, by Disease Indication
Wet age-related macular degeneration
Dry age-related macular degeneration
Others
Global Macular Degeneration Treatment Market, by Drug Class
Anti-vascular endothelial growth factor
Others
Global Macular Degeneration Treatment Market, by Distribution Channel
Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Global Macular Degeneration Treatment Market, by Region
North America
U.S
Canada
Europe
Germany
U.K
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
Australia & New Zealand
India
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Macular Degeneration Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Indication Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.1.1. Growing prevalence of AMD owing to increase in the geriatric population
4.3.1.2. Increase in health care spending and improvement in health care infrastructure
4.3.1.3. New product launches and high annual cost of therapy (ACOT)
4.3.1.4. Rise in number of eye care centers leading to increased product utilization
4.3.2. Restraints
4.3.2.1. Patent expiry of three well-established anti-VEGFs
4.3.2.2. Non-compliance with treatment
4.3.2.3. Lack of awareness
4.3.3. Opportunities
4.4. Global Macular Degeneration Treatment Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insight
5.1. Regulatory Scenario by Region/Globally
5.2. Key Mergers & Acquisitions
5.3. AMD Clinical Trial Analysis
5.4. Reimbursement Scenario
5.5. AMD Prevalence Rate Globally with Key Countries
6. Global Macular Degeneration Treatment Market Analysis and Forecast, by Disease Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
6.3.1. Wet age-related macular degeneration
6.3.2. Dry age-related macular degeneration
6.3.3. Others
6.4. Global Macular Degeneration Treatment Market Attractiveness, by Disease Indication
7. Global Macular Degeneration Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
7.3.1. Anti-vascular endothelial growth factor
7.3.2. Others
7.4. Global Macular Degeneration Treatment Market Attractiveness, by Drug Class
8. Global Macular Degeneration Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospitals
8.3.2. Ophthalmic Clinics
8.3.3. Ambulatory Surgical Centers
8.4. Global Macular Degeneration Treatment Market Attractiveness, by Distribution Channel
9. Global Macular Degeneration Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Macular Degeneration Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Macular Degeneration Treatment Market Attractiveness, by Region
10. North America Macular Degeneration Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
10.2.1. Wet age-related macular degeneration
10.2.2. Dry age-related macular degeneration
10.2.3. Others
10.3. North America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Anti-vascular endothelial growth factor
10.3.2. Others
10.4. North America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospitals
10.4.2. Ophthalmic Clinics
10.4.3. Ambulatory Surgical Centers
10.5. North America Macular Degeneration Treatment Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Macular Degeneration Treatment Market Attractiveness Analysis
10.6.1. By Disease Indication
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Macular Degeneration Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
11.2.1. Wet age-related macular degeneration
11.2.2. Dry age-related macular degeneration
11.2.3. Others
11.3. Europe Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Anti-vascular endothelial growth factor
11.3.2. Others
11.4. Europe Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospitals
11.4.2. Ophthalmic Clinics
11.4.3. Ambulatory Surgical Centers
11.5. Europe Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Macular Degeneration Treatment Market Attractiveness Analysis
11.6.1. By Disease Indication
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Macular Degeneration Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
12.2.1. Wet age-related macular degeneration
12.2.2. Dry age-related macular degeneration
12.2.3. Others
12.3. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Anti-vascular endothelial growth factor
12.3.2. Others
12.4. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospitals
12.4.2. Ophthalmic Clinics
12.4.3. Ambulatory Surgical Centers
12.5. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis
12.6.1. By Disease Indication
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Macular Degeneration Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
13.2.1. Wet age-related macular degeneration
13.2.2. Dry age-related macular degeneration
13.2.3. Others
13.3. Latin America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Anti-vascular endothelial growth factor
13.3.2. Others
13.4. Latin America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospitals
13.4.2. Ophthalmic Clinics
13.4.3. Ambulatory Surgical Centers
13.5. Latin America Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Macular Degeneration Treatment Market Attractiveness Analysis
13.6.1. By Disease Indication
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Macular Degeneration Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
14.2.1. Wet age-related macular degeneration
14.2.2. Dry age-related macular degeneration
14.2.3. Others
14.3. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Anti-vascular endothelial growth factor
14.3.2. Others
14.4. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospitals
14.4.2. Ophthalmic Clinics
14.4.3. Ambulatory Surgical Centers
14.5. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis
14.6.1. By Disease Indication
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Market Share Analysis by Company & Competition Matrix (By Tier and Size of companies)
15.2. Company Profiles
15.2.1. Allergan plc.
15.2.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.1.2. Business Overview
15.2.1.3. Product Portfolio
15.2.1.4. Financial Overview
15.2.1.5. SWOT Analysis
15.2.2. Novartis AG
15.2.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.2.2. Business Overview
15.2.2.3. Product Portfolio
15.2.2.4. Financial Overview
15.2.2.5. SWOT Analysis
15.2.3. Pfizer Inc.
15.2.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.3.2. Business Overview
15.2.3.3. Product Portfolio
15.2.3.4. Financial Overview
15.2.3.5. SWOT Analysis
15.2.4. Santen Pharmaceuticals Co. Ltd.
15.2.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.4.2. Business Overview
15.2.4.3. Product Portfolio
15.2.4.4. Financial Overview
15.2.4.5. SWOT Analysis
15.2.5. Valeant Pharmaceuticals International, Inc.
15.2.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.5.2. Business Overview
15.2.5.3. Product Portfolio
15.2.5.4. Financial Overview
15.2.5.5. SWOT Analysis
15.2.6. Bayer AG
15.2.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.6.2. Business Overview
15.2.6.3. Product Portfolio
15.2.6.4. Financial Overview
15.2.6.5. SWOT Analysis
15.2.7. F. Hoffmann-La Roche Ltd.
15.2.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.7.2. Business Overview
15.2.7.3. Product Portfolio
15.2.7.4. Financial Overview
15.2.7.5. SWOT Analysis
15.2.8. Sanofi
15.2.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.8.2. Business Overview
15.2.8.3. Product Portfolio
15.2.8.4. Financial Overview
15.2.8.5. SWOT Analysis
15.2.9. REGENERON PHARMACEUTICALS, INC.
15.2.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
15.2.9.2. Business Overview
15.2.9.3. Product Portfolio
15.2.9.4. Financial Overview
15.2.9.5. SWOT Analysis
Table 01: Global Macular Degeneration Treatment Market Pipeline Analysis Phase I
Table 02: Global Macular Degeneration Treatment Market Pipeline Analysis Phase II
Table 03: Global Macular Degeneration Treatment Market Pipeline Analysis Phase III
Table 04: Regulatory Scenario, by Region/Globally
Table 05: Key Mergers & Acquisitions
Table 06: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 07: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 08: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 09: Global Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 10: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 11: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 12: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 13: North America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 14: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 15: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 16: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Europe Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 19: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 20: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Asia Pacific Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 23: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 24: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 25: Latin America Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 26: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 27: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 28: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 29: Middle East & Africa Macular Degeneration Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026